PFE vs SLB: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and SLB N.V. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
VS
SLB N.V. · Energy
$56.15
+45.0% upside to fair value
Grade B
QuantHub Verdict
SLB has more upside to fair value
(+45.0%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
SLB |
| Current Price |
$26.33 |
$56.15 |
| Fair Value Estimate |
$33.85 |
$81.42 |
| Upside to Fair Value |
+28.6%
|
+45.0%
|
| Market Cap |
$149.8B |
$84.3B |
| Forward P/E |
19.3x
|
24.3x
|
| EV / EBITDA |
12.9x
|
17.5x
|
| Price / Sales |
2.4x
|
2.4x
|
| Price / FCF |
16.5x
|
17.6x
|
| Revenue Growth YoY |
-1.2%
|
+2.7%
|
| Gross Margin |
70.3%
|
13.6%
|
| Operating Margin |
24.7%
|
11.5%
|
| Return on Equity |
8.7%
|
12.2%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
6.06%
|
5.69%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
SLB N.V. is the world's largest oilfield services company operating primarily in the energy sector with a focus on oil and gas equipment and services. The company benefits from a diversified revenue base across well construction, production systems, reservoir characterization, and digital integration, with fiscal year 2024 revenues totaling over $37 billion. Despite modest revenue growth of 2.7% …
Accumulation Zones
| Metric |
PFE |
SLB |
| Zone Low |
$25.39 |
$61.06 |
| Zone High |
$28.77 |
$69.21 |
| In Buy Zone? |
Yes
|
Yes
|